Pharmacognosy · PMS & Hormonal Balance

Chasteberry

Vitex agnus-castus (Verbenaceae) — a Mediterranean shrub whose Latin name, "chaste lamb," reflects a centuries-old reputation as the monastery herb monks chewed to curb temptation. Its labdane diterpenes act as dopamine agonists that inhibit prolactin secretion — the mechanism behind its modern, well-studied use for premenstrual syndrome, cyclical breast tenderness, and menstrual cycle regulation.

46 Primary Refs
8 Properties
Fruit Parts Used
✦ Researched
Last Updated August 4, 2026
Primary Source Wikiphyto · NCBI PubMed · EMA/HMPC
Family Verbenaceae
French Pharmacopoeia List A · Verbenaceae

Biological Overview

Vitex agnus-castus is a Mediterranean shrub of humid habitats with a peppery scent, also grown as an ornamental plant. It reaches 1–2 meters in height, with long inflorescences of short, compact clusters bearing whorls of fragrant, tubular, bilabiate flowers in shades of blue or violet.

HabitShrub, 1–2m
Native RangeMediterranean, Humid Sites
Well-Established Dose20mg dry extract/day
Regulatory StatusFr. Pharmacopoeia List A
Botanical Classification

Taxonomy & Identification

Latin Name
Vitex agnus-castus L.
Family
Verbenaceae (Lamiaceae per APG III)
Common Names
Chasteberry, Chaste Tree, Monk's Pepper
Parts Used
Flowering tops and fruit (berries)
Minimum Age for Use
EMA advises against use under 18
Origin
Mediterranean, cultivated ornamentally
Ethnobotany & Traditional Use

History & Tradition

Chasteberry symbolized chastity in the Iliad, and was cited by Dioscorides and Pliny. Its Latin name, agnus castus — "chaste lamb" — evokes its reputed anaphrodisiac properties.

It was cultivated near monasteries for this very purpose, earning it the name "monk's pepper" — monks chewed its berries to curb temptations of the flesh. It also featured in the historical formulation known as "Michael's Essence of Chastity."

In the Middle Ages, it was used "to repress lust, make a man chaste as a lamb, tighten the womb, and bring on the flowers" — a period euphemism for menstruation, reflecting its long-standing gynecological reputation.

⚠ Historical Reputation vs Modern Use

Chasteberry's Latin name reflects a centuries-old reputation as an anaphrodisiac used by monks to suppress libido — a striking contrast to its modern clinical use, which centers on hormonal regulation for PMS and menstrual cycle disorders rather than any anaphrodisiac effect.

Timeline

Symbol of Chastity in Antiquity

Antiquity

Symbolized chastity in the Iliad; cited by Dioscorides and Pliny for its reputed anaphrodisiac properties.

Monastic "Monk's Pepper" Use

Medieval

Cultivated near monasteries and chewed by monks to curb temptation, earning the name "monk's pepper."

Medieval Gynecological Use

Medieval

Used "to repress lust, make a man chaste as a lamb, tighten the womb, and bring on the flowers" (menstruation).

Modern PMS & Hormonal Research

20th Century–Present

Dopaminergic and prolactin-modulating mechanisms were characterized, and multiple RCTs and meta-analyses examined its use for premenstrual syndrome. 228

The Key Compound

Rotundifurane — Deep Dive

The labdane diterpene behind chasteberry's dopaminergic, prolactin-modulating reputation.

🧬

Labdane Diterpene Structure

Rotundifurane and related labdane diterpenes (vitexilactone, diacetoxy-labdane-diene) share strong structural analogies with steroids. 8

🎯

Dopamine D2 Receptor Agonism

Rotundifurane and 6β,7β-diacetoxy-13-hydroxy-labda-8,14-diene show affinity for the dopamine D2 receptor, acting as dopamine agonists blocked by haloperidol. 8

📉

Prolactin Inhibition via Dopaminergic Action

This central and peripheral dopaminergic action inhibits prolactin secretion — the core mechanism behind chasteberry's effect on cyclical breast tenderness and pelvic swelling. 239

⚖️

Dose-Dependent, Biphasic Prolactin Effect

A Vitex extract has been shown to raise blood prolactin at a low dose (120 mg) but reduce it at a higher dose (480 mg) — a biphasic dose-response relationship. 3

⚠ Biphasic Dose-Response

More isn't simply "stronger" with this herb.

Chasteberry doesn't follow a simple dose curve — low doses have been shown to raise prolactin while higher doses lower it. This underscores why standardized, studied dosing matters more than casual increases.

Pharmaceutical Preparations

Parts Used & Available Forms

The flowering tops and fruit are used medicinally, prepared across three standardized forms.

Mother Tincture

Tincture of the fruit, used at practitioner-directed dilution.

Mother Tincture · Fruit

Standardized Plant Extract

Fresh-plant standardized extract (EPS) of the aerial parts.

Standardized Extract

Dry Hydroalcoholic Extract

Concentrated dry extract, the standardized form behind most clinical trials and EMA-recognized dosing.

Dry Extract

Clinical Dosimetry

Dosages

The EMA distinguishes well-established use from traditional use; practitioners often prescribe use during the second half of the cycle, roughly days 8–21.

Form Dose Frequency Context Notes
Dry Extract (DER 6–12:1) 20 mg Once daily, continuous EMA well-established use Taken continuously for three months; 60% ethanol extraction solvent. 38
Fruit Powder 400 mg 2× daily EMA traditional use Traditional-use dosing option.
Tincture (1:5, 68–70% ethanol) 165 mg Once daily EMA traditional use Traditional-use dosing option.
Dry Extract (DER 7–13:1) 4 mg Once daily EMA traditional use 60% ethanol extraction solvent.
Mother Tincture (Practitioner Regimen) 50 drops 2–3× daily Days 8–21 of cycle Common practitioner-prescribed regimen during the luteal phase.
Phytochemistry

Composition

Plant and essential-oil composition — no gemmotherapy (bud) fraction is documented for this species.

Fruit & Flowering Tops — Primary Constituents

FlavonoidsCasticin, vitexin, C-glycosides, penduletin, chrysosplenol, luteolin, luteolin-7-glucoside, homoorientin 1
Present
IridoidsAucuboside, agnuside, eurostoside
Present
Labdane DiterpenesRotundifurane, vitexilactone, diacetoxy-labdane-diene and its 6β,7β-hydroxy derivative
Present
Essential OilCineole-type, plus various fatty acids
Present
3-Ketosteroids & EcdysonesReported in other Vitex species (uncertain in V. agnus-castus itself)
Trace / (?)

Essential Oil — Primary Constituents

alpha-PineneDominant monoterpene
14.83%
LimoneneMonoterpene
10.29%
beta-CaryophylleneSesquiterpene
6.9%
SabineneMonoterpene
5.27%
beta-FarneseneSesquiterpene
5.9%

Plant Properties — Pharmacodynamics

Eight pharmacodynamic properties are documented for chasteberry, anchored in its dopaminergic, prolactin-modulating activity.

8 Properties Dopaminergic Prolactin-Modulating Clinical + Preclinical
🌙

Emmenagogue & Sedative

Traditionally regarded as emmenagogue and sedative, alongside a reported anaphrodisiac effect in men.

📉

Prolactin-Modulating

Inhibits prolactin secretion in vitro and in vivo, with a biphasic dose-response in humans. 23

🤰

Fertility-Supportive

Traditionally regarded as favoring conception, consistent with its studied use for luteal phase support.

⚖️

Anti-Estrogenic & Anti-Androgenic

Shows anti-estrogenic and anti-androgenic activity in the whole plant, distinct from the complex estrogenic signal seen in related Vitex rotundifolia. 4

🔄

Phyto-Progesterone-Like Action

Raises mid-cycle progesterone concentrations — termed "phyto-progesterone," though its mechanism differs substantially from phyto-estrogens.

🎯

Dopaminergic (D2 Receptor)

Rotundifurane and related diterpenes show D2 dopamine receptor affinity, acting like dopamine and blocked by haloperidol. 8

🌛

Melatonin-Stimulating

Induces a significant, dose-dependent increase in melatonin secretion. 7

🧫

Anti-Proliferative (Leukemia)

Rotundifurane, polymethoxyflavones, and luteolin inhibit proliferation and induce apoptosis in HL-60 myeloid leukemia cells. 91011

Clinical Applications

Clinical Indications

Chasteberry's primary use is premenstrual syndrome, with a substantial and growing clinical evidence base plus broader menstrual and hormonal indications.

🩸
Premenstrual Syndrome (PMS)
Primary Indication
  • Broad Symptom Coverage: studied for PMS with insomnia, water retention, premenstrual dysphoria, premenstrual depression, and cyclical mastalgia. 15192123
  • Meta-Analyses (Mixed Certainty): one meta-analysis shows a substantial effect in placebo-controlled trials but flags recruitment-related bias risk; a more recent CONSORT-informed meta-analysis found extracts effective but flagged incomplete drug description in the underlying trials. 2830
  • 2024 Cohort Study: a retrospective longitudinal cohort found clear quality-of-life improvement in patients with dysmenorrhea and mastalgia. 31
🔄
Menstrual Cycle & Fertility
Traditional & Clinical Indication
  • Cycle Irregularities: polymenorrhea, oligomenorrhea, and general menstrual disorders.
  • Luteal Support: cycle abnormalities with luteal insufficiency and latent hyperprolactinemia; secondary ovarian insufficiency, except in cases of prolactinoma or hypothyroidism. 32
🌡️
Menopausal Transition
Traditional / Preliminary Indication
  • Hot Flashes & Vaginal Dryness: traditionally used for menopausal hot flashes and vaginal dryness. 33
  • Essential Oil (Aromatherapy, Tentative): explored for menopausal balance, flagged as uncertain in the source itself. 3536
⚠️
Use Considerations
Clinical Precautions
  • Medication Interactions: not recommended with dopamine agonist/antagonist drugs or with estrogens/anti-estrogens like tamoxifen. 40
  • Pregnancy & Age Restrictions: contraindicated in pregnancy and lactation; not appropriate for prepubertal children; EMA advises against use under 18. 38
Pharmacodynamics

Mode of Action

Chasteberry's regulatory effect on the menstrual cycle converges on dopaminergic signaling and pulsatile hypothalamic-pituitary hormone secretion.

🧬

Labdane Diterpene–Dopamine Pathway

Activity is attributed to labdane diterpenes, notably rotundifurane, which act as dopamine agonists both centrally and peripherally via inhibition of prolactin secretion; labdane diterpenes show strong structural analogies to steroids.

🧠

Mesolimbic & Extrapyramidal Dopaminergic Action

Central action on dopaminergic systems, particularly the mesolimbic and extrapyramidal pathways, is proposed to explain effects on the psychological, motor, and somatic aspects of PMS; dopaminergic and prolactin-inhibiting compounds are clinically linked to improvement in premenstrual mastalgia and PMS. 37

📡

GnRH Pulsatility

GnRH (gonadotropin-releasing hormone) is a decapeptide, highly conserved across vertebrates, whose pulsatile secretion — discovered in the 1970s — drives pulsatile LH and FSH release from a coordinated hypothalamic neuron network.

📊

Normalization of Pulsatile Gonadotropin Secretion

Chasteberry normalizes pulsatile GnRH secretion and the gonadotropins LH and FSH, contributing to its regulatory effect on the menstrual cycle.

Comparative Analysis

Chasteberry vs Fluoxetine

A botanical dopaminergic option set directly against an SSRI in a head-to-head PMDD trial.

Criterion Chasteberry Fluoxetine
Mechanism Dopaminergic action reducing prolactin; normalizes GnRH/LH/FSH pulsatility Selective serotonin reuptake inhibition
Primary Target Hormonal/endocrine regulation — PMS, PMDD, cyclical mastalgia Mood and affective symptoms broadly, including PMDD
Evidence Base A direct RCT compared it to fluoxetine for PMDD; multiple PMS RCTs and meta-analyses. 22 Extensive RCT evidence for PMDD and depression generally
Onset Typically used continuously over roughly 3 months for full effect Can take weeks to reach full effect; sometimes dosed cyclically for PMDD
Side Effect Profile Generally well tolerated: mild nausea, headache, GI upset, menstrual changes, acne Broader range including sexual side effects, GI upset, and discontinuation effects
Regulatory Status Fr. Pharmacopoeia List A; EMA well-established herbal use Prescription antidepressant (SSRI)

Bottom Line

In a direct comparison trial, chasteberry and fluoxetine showed comparable improvement in premenstrual dysphoric disorder symptoms, though through entirely different mechanisms — chasteberry via dopaminergic/prolactin regulation, fluoxetine via serotonin reuptake inhibition. For primarily physical PMS symptoms like mastalgia and bloating, chasteberry is often favored; for predominantly mood-based PMDD, either may be considered, ideally with medical guidance.

Risk Profile

Safety & Interactions

Chasteberry appears low-risk overall — the source describes it as apparently atoxic — but specific medication interactions and pregnancy avoidance remain genuine precautions.

⚠ Genuine Risks Specific to This Plant

Read Before Using Chasteberry

  • Not for use with dopaminergic/antidopaminergic drugs: not recommended alongside dopamine agonists (e.g. anti-Parkinson's drugs) or dopamine antagonists (e.g. anti-emetics) due to additive or antagonistic effects. 40
  • Not for use with estrogens/anti-estrogens: combination with estrogens or anti-estrogens such as tamoxifen is not recommended.
  • Contraindicated in pregnancy and lactation.
  • Not appropriate for prepubertal use: the EMA advises against use before age 18. 38
✓ How to Use Chasteberry More Safely

A Practical Safety Checklist

  1. Take consistently. Use once daily, ideally for a full 3-month course to assess effect, per EMA well-established-use guidance.
  2. Avoid mixing with dopamine-active medications. Skip if taking anti-Parkinson's drugs or anti-emetics without medical guidance.
  3. Avoid combining with hormonal therapies. Not recommended alongside estrogens or anti-estrogen drugs like tamoxifen.
  4. Never use during pregnancy or breastfeeding.
  5. Not for use under 18. The EMA specifically advises against use in this age group.
  6. Watch for mild side effects. Nausea, headache, GI upset, menstrual changes, acne, itching, or rash are the most commonly reported; stop and consult a provider if they persist.
⚠️

Adverse Effects

  • Overall Tolerability: appears atoxic and apparently free of major risk based on available data.
  • No Gonadotropin Disruption: does not appear to directly affect FSH or LH secretion. 39
  • Common Mild Effects: nausea, headache, gastrointestinal disturbances, menstrual changes, acne, itching, and erythematous rash.
🚫

Contraindications & Interactions

  • Dopaminergic Medications: avoid combining with dopamine agonists or antagonists (e.g. anti-Parkinson's drugs, anti-emetics) due to additive or antagonistic effects. 40
  • Hormonal Therapies: avoid combining with estrogens or anti-estrogens such as tamoxifen.
  • Pregnancy, Lactation & Youth: contraindicated in pregnancy and breastfeeding; not appropriate for prepubertal children; EMA advises against use under 18. 38
Clinical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Consult a qualified healthcare provider before starting chasteberry, particularly if pregnant, breastfeeding, under 18, or taking dopamine- or hormone-active medications.
Common Questions

Frequently Asked Questions

What is chasteberry used for?
Chasteberry is used primarily for premenstrual syndrome (PMS), including cyclical breast tenderness, water retention, and mood symptoms, as well as menstrual cycle irregularities and luteal phase support.
How does chasteberry work?
Labdane diterpenes, particularly rotundifurane, act as dopamine agonists at the D2 receptor, inhibiting prolactin secretion. This dopaminergic action, along with normalization of pulsatile GnRH, LH, and FSH, underlies its effect on the menstrual cycle and PMS symptoms.
What is the typical chasteberry dosage?
The EMA recognizes 20 mg of dry extract once daily, taken continuously for three months, as well-established use. Traditional-use options include 400 mg of fruit powder twice daily, or 165 mg of tincture once daily. Practitioners often prescribe use during the second half of the cycle, roughly days 8–21.
Is chasteberry safe? Does it have side effects?
Chasteberry appears to be low-risk, with the most common side effects being mild nausea, headache, gastrointestinal disturbances, menstrual changes, acne, itching, or a rash.
Can I take chasteberry with hormonal birth control or other hormone medications?
Combining chasteberry with estrogens or anti-estrogen drugs like tamoxifen is not recommended. It should also not be combined with dopamine agonist or antagonist medications, such as anti-Parkinson's drugs or anti-emetics, without medical guidance.
Does chasteberry affect fertility?
Chasteberry is traditionally thought to favor conception and has been studied for luteal phase defects linked to latent hyperprolactinemia, working through its prolactin-inhibiting, dopaminergic action.
Chasteberry vs fluoxetine — which is better for PMDD?
A direct comparison trial found chasteberry and fluoxetine showed comparable improvement in premenstrual dysphoric disorder symptoms, though through entirely different mechanisms. Chasteberry is often favored for predominantly physical PMS symptoms, while either may be considered for mood-based PMDD, ideally with medical guidance.
Is chasteberry safe during pregnancy?
No. Chasteberry is contraindicated during pregnancy and breastfeeding.
Sources

Bibliography

↑1. Long C. Étude phytochimique, évaluation de potentialités biologiques de Vitex agnus castus L. (Verbenaceae). Doctoral thesis, INPT Toulouse, 1995.
↑2. Sliutz G, Speiser P, Schultz AM, Spona J, Zeillinger R. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res. 1993;25(5):253–255.
PubMed: PMID 8330858 →
↑3. Merz PG, Gorkow C, Schrödter A, et al. The effects of a special Agnus castus extract (BP1095E1) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes. 1996;104(6):447–453.
PubMed: PMID 9021345 →
↑4. Hu Y, Hou TT, Zhang QY, et al. Evaluation of the estrogenic activity of the constituents in the fruits of Vitex rotundifolia L. for the potential treatment of premenstrual syndrome. J Pharm Pharmacol. 2007;59(9):1307–1312.
PubMed: PMID 17883902 →
5. Thompson M, Wilson M, Gobbo G, Muller M, Pusey A. Hyperprogesteronemia in response to Vitex fischeri consumption in wild chimpanzees (Pan troglodytes schweinfurthii). Am J Primatol. 2008;70(11):1064–1071.
6. Ahangarpour A, Najimi SA, Farbood Y. Effects of Vitex agnus-castus fruit on sex hormones and antioxidant indices in a d-galactose-induced aging female mouse model. J Chin Med Assoc. 2016;79(11):589–596.
PubMed: PMID 27595438 →
↑7. Dericks-Tan JS, Schwinn P, Hildt C. Dose-dependent stimulation of melatonin secretion after administration of Agnus castus. Exp Clin Endocrinol Diabetes. 2003;111(1):44–46.
PubMed: PMID 12605350 →
↑8. Hoberg E, Orjala J, Meier B, Sticher O. Diterpenoids from the fruits of Vitex agnus-castus. Phytochemistry. 1999;52(8):1555–1558.
↑9. Ko WG, Kang TH, Lee SJ, Kim YC, Lee BH. Rotundifuran, a labdane type diterpene from Vitex rotundifolia, induces apoptosis in human myeloid leukaemia cells. Phytother Res. 2001;15(6):535–537.
PubMed: PMID 11536386 →
↑10. Ko WG, Kang TH, Lee SJ, et al. Polymethoxyflavonoids from Vitex rotundifolia inhibit proliferation by inducing apoptosis in human myeloid leukemia cells. Food Chem Toxicol. 2000;38(10):861–865.
PubMed: PMID 11039319 →
↑11. Ko WG, Kang TH, Lee SJ, Kim YC, Lee BH. Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells. Phytother Res. 2002;16(3):295–298.
PubMed: PMID 12164283 →
12. Šošić-Jurjević B, Ajdžanović V, Filipović B, et al. Functional morphology of pituitary-thyroid and -adrenocortical axes in middle-aged male rats treated with Vitex agnus castus essential oil. Acta Histochem. 2016;118(7):736–745.
13. Khalilzadeh E, Vafaei Saiah G, Hasannejad H, et al. Antinociceptive effects, acute toxicity and chemical composition of Vitex agnus-castus essential oil. Avicenna J Phytomed. 2015;5(3):218–230.
PubMed: PMID 26101755 →
14. Asdadi A, Hamdouch A, Oukacha A, et al. Study on chemical analysis, antioxidant and in vitro antifungal activities of essential oil from wild Vitex agnus-castus L. seeds. J Mycol Med. 2015;25(4):e118–e127.
PubMed: PMID 26611404 →
↑15. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med. 2000;9(3):315–320.
PubMed: PMID 10787228 →
16. Berger D, Schaffner W, Schrader E, Meier B, Brattström A. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with premenstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264(3):150–153.
PubMed: PMID 11129515 →
17. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322(7279):134–137.
PubMed: PMID 11159568 →
18. Maleki-Saghooni N, Karimi FZ, Behboodi Moghadam Z, Mirzaii Najmabadi K. The effectiveness and safety of Iranian herbal medicines for treatment of premenstrual syndrome: a systematic review. Avicenna J Phytomed. 2018;8(2):96–113.
PubMed: PMID 29632841 →
↑19. Ma L, Lin S, Chen R, et al. Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Aust N Z J Obstet Gynaecol. 2010;50(2):189–193.
PubMed: PMID 20522079 →
20. Ma L, Lin S, Chen R, Wang X. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol Endocrinol. 2010;26(8):612–616.
PubMed: PMID 20334585 →
↑21. Cerqueira RO, Frey BN, Leclerc E, Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2017;20(6):713–719.
PubMed: PMID 29063202 →
↑22. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2003;18(3):191–195.
PubMed: PMID 12672170 →
↑23. Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast. 1999;8(4):175–181.
PubMed: PMID 14731436 →
24. Carmichael AR. Can Vitex agnus castus be used for the treatment of mastalgia? What is the current evidence? Evid Based Complement Alternat Med. 2008;5(3):247–250.
PubMed: PMID 18830450 →
25. Ooi SL, Watts S, McClean R, Pak SC. Vitex agnus-castus for the treatment of cyclic mastalgia: a systematic review and meta-analysis. J Womens Health (Larchmt). 2020;29(2):262–278.
PubMed: PMID 31464546 →
26. Zamani M, Neghab N, Torabian S. Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta Med Iran. 2012;50(2):101–106.
PubMed: PMID 22359078 →
27. He Z, Chen R, Zhou Y, et al. Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multi-center placebo controlled study in China. Maturitas. 2009;63(1):99–103.
PubMed: PMID 19269753 →
↑28. Verkaik S, Kamperman AM, van Westrhenen R, Schulte PFJ. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217(2):150–166.
PubMed: PMID 28237870 →
29. Lorette G, Maruani A. Les recommandations CONSORT (CONsolidated Standards Of Reporting Trials). Ann Dermatol Venereol. 2013;140(6-7):431–435.
↑30. Csupor D, Lantos T, Hegyi P, et al. Vitex agnus-castus in premenstrual syndrome: a meta-analysis of double-blind randomised controlled trials. Complement Ther Med. 2019;47:102190.
PubMed: PMID 31780016 →
↑31. Höller M, Steindl H, Abramov-Sommariva D, et al. Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study. Arch Gynecol Obstet. 2024;309(5):2089–2098.
PubMed: PMID 38393671 →
↑32. Milewicz A, Gejdel E, Sworen H, et al. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Arzneimittelforschung. 1993;43(7):752–756.
PubMed: PMID 8369008 →
↑33. Seidl MM, Stewart DE. Alternative treatments for menopausal symptoms: systematic review of scientific and lay literature. Can Fam Physician. 1998;44:1299–1308.
34. von Fellenberg-Ziegler A. Homöopathische Arzneimittellehre. Haug-Verlag, 1998.
↑35. Lucks BC, Sørensen J, Veal L. Vitex agnus-castus essential oil and menopausal balance: a self-care survey. Complement Ther Nurs Midwifery. 2002;8(3):148–154.
PubMed: PMID 12353616 →
↑36. Chopin Lucks B. Vitex agnus castus essential oil and menopausal balance: a research update. Complement Ther Nurs Midwifery. 2003;9(3):157–160.
PubMed: PMID 12852933 →
↑37. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlová-Wuttke D. Chaste tree (Vitex agnus-castus) — pharmacology and clinical indications. Phytomedicine. 2003;10(4):348–357.
PubMed: PMID 12809367 →
↑38. Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Vitex agnus-castus L., fructus. EMA/HMPC/606742/2017, March 27, 2018.
EMA Monograph (PDF) →
↑39. Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol. 1994;102(6):448–454.
PubMed: PMID 7890021 →
↑40. Daniele C, Thompson Coon J, Pittler MH, Ernst E. Vitex agnus castus: a systematic review of adverse events. Drug Saf. 2005;28(4):319–332.
PubMed: PMID 15783241 →

Additional Sources

Geller SE, Studee L. Contemporary alternatives to plant estrogens for menopause. Maturitas. 2006;55 Suppl 1:S3–S13.
Brown D. The use of Vitex agnus castus for hyperprolactinemia. Q Rev Nat Med. 1997:19–21.
Hajdú Z, Hohmann J, Forgo P, et al. Diterpenoids and flavonoids from the fruits of Vitex agnus-castus and antioxidant activity of the fruit extracts and their constituents. Phytother Res. 2007;21(4):391–394.
PubMed: PMID 17262892 →
Ono M, Nagasawa Y, Ikeda T, et al. Three new diterpenoids from the fruit of Vitex agnus-castus. Chem Pharm Bull (Tokyo). 2009;57(10):1132–1135.
PubMed: PMID 19801874 →
Chen SN, Friesen JB, Webster D, et al. Phytoconstituents from Vitex agnus-castus fruits. Fitoterapia. 2011;82(4):528–533.
PubMed: PMID 21163339 →
European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). List of references for assessment of Vitex agnus-castus L., fructus.
EMA Reference List (PDF) →